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Purpose
The TLR 7/8 agonist, Resiquimod has been shown to
induce local activation of immune cells, production of
cytokines, and antigen-presentation by dendritic cells,
features desirable for cancer vaccine adjuvants. In this
study, we evaluated the safety and immunogenicity of
vaccination with NY-ESO-1 protein emulsified in Mon-
tanide ISA-51 VG when given with or without Resiqui-
mod in surgically resected stage IIB-IV melanoma
patients.
Experimental design
This is a two-part study design. Part I represents an
open-label dose-escalation with Resiquimod using 2
cohorts treated with 100μg NY-ESO-1 protein emulsi-
fied in 1.25mL Montanide (day1) followed by topical
application of 1000mg of the 0.2% Resiquimod gel on
days 1 and 3 for cohort-1 (N=3) or days 1, 3, and 5 for
cohort-2 (N=3). The cycles were repeated every 3
weeks, total of 4 cycles. For part II of the study, patients
were blindly randomized to receive 100μg NY-ESO-1
protein emulsified in 1.25mL Montanide (day1) followed
by topical application of placebo gel (Arm-A; N=8) or
1000mg of 0.2% Resiquimod gel (Arm-B; N=12) using
the dosing regimen established in Part I. Blood samples
were collected at baseline, one week after each cycle of
vaccination, and at follow-up visit for the assessment of
NY-ESO-1-specific humoral and cellular immune
responses.
Results
The vaccines were generally well-tolerated, with no grade
4 adverse events or study-related deaths. Most study par-
ticipants experienced mild adverse reactions reported as
Grade 1 or 2 per CTCAE criteria v. 4. One patient
experienced a grade 3 syncopal episode that was unre-
lated to the study drugs and another patient had a grade
3 injection site necrosis that was possibly related to the
study drugs. NY-ESO-1 specific antibody responses were
induced in both study arms although higher mean anti-
body titers were observed in Arm B. NY-ESO-1 specific
CD4+ T cell responses were induced in patients in both
study arms. However, significant NY-ESO-1 CD8+ T cell
responses were detected only in Arm B.
Conclusions
The current study shows that Resiquimod is safe and
contributes to the induction of immune responses in
patients.
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